Senolytic is a potential new anti-aging drug, and it is worth exploring whether it has an inhibitory effect on osteoporosis. Osteoporosis models in mice were established by gavage of retinoic acid(RA), and Senolytic drugs (dasatinib and quercetin) were used to treat for 8w. Serological indexes were measured, and bone mineral density was detected by dual-energy X-ray absorptiometry, then parameters of trabecular bone were quantified by μCT, by which three-dimensional images of lumbar trabecular bone were rebuild for comprehensive analysis. In osteoporosis model mice the content of serum calcium and alkaline phosphatase in mice were increased, the bone mineral density decreased, bone volume fraction and trabecular number decreased significantly, and the trabecular separation increased significantly. After applying the Senolytic drug, the serum calcium of group A and B were significantly lower than that of the blank control group. The alkaline phosphatase content in the two groups was (272.5±42.7)U/L and (258.4±90.2)U/L, which was also significantly lower than that in the blank control group (389.0±31.1)U/L. After the treatment of Senolytic, the bone mineral density of group A and group B were improved, the bone volume fraction were increased compared with the blank control group. The trabecular bone separation of the two groups was significantly reduced. Therefore, these reduced osteoporosis. From our study, it can be confirmed that the senolytic drug has a certain alleviating effect on osteoporosis.
Decreased Bone Volume and Bone Mineral Density in the Tibial Trabecular Bone Is Associated with Per2 Gene by 405 nm Laser Stimulation